Positive results for BTK inhibitor for primary membranous nephropathy
Everest Medicines has revealed positive results in the ongoing Phase Ib/IIa clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011). In an analysis of the data, results from the trial showed that for patients in the low-dose cohort who have… Read More